Resource Summary

Clinical Question:
What is the efficacy and safety of linaclotide in constipation predominant irritable bowel syndrome (IBS-C)?

Bottom Line:
Compared to placebo^ for every seven patients treated with linaclotide one more will be a “responder” [30% improvement in pain and one additional “complete” spontaneous bowel movement (CSBM) per week for six weeks in 12]. Overall^ patients experience ~3 additional “spontaneous” bowel movements (BM) per week^ at the price of $15 per BM. For every 21 patients treated^ one will stop due to diarrhea. Post-marketing surveillance should help clarify long-term safety.

https://www.acfp.ca/tools-for-practice/

Publication Date: 2017-6-12
Last Updated on PCR: 2017-07-05 00:03:23